

## Declaration of Interests Register

**Technology Appraisal Committee A**

**Publication Date: 17/10/2019**

**Topic: TA607 Rivaroxaban for preventing major cardiovascular events in people with coronary or peripheral artery disease [ID1397]**

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments
				Interest arose	Interest declared	Interest ceased	
Dr Keith Fox	Expert adviser	Direct non-financial professional interest	Co-chair of COMPASS trial		June 2019	Ongoing	Declare and participate.
Adrian Griffin	Committee member	Direct financial	His employer, Johnson & Johnson, own the rights to market rivaroxaban outside the UK		June 2019	Ongoing	Excluded from the meeting.
Olivia Wu	Committee member	Direct financial	Received honorarium from Bayer for advice on evidence synthesis relating to DOACs in patients with AF.		June 2019		Excluded from the meeting.

Link to Committee A interests register : <https://www.nice.org.uk/Media/Default/Get-involved/Meetings-In-Public/Technology-appraisal-committee/TAC-A-interests-register.pdf>

### GUIDANCE NOTES FOR COMPLETION OF THE INTERESTS REGISTER

**Relevant dates:** Detail here the date the interest arose, the date it was first declared and when it ceased, if applicable. For example, if an individual has ceased to hold shares or undertake relevant private practice.